# EDGAR Filing Document

**Accession Number:** 0001135951
**File Stem:** 0001575872-25-000570
**Filing Date:** 2025-9
**Character Count:** 15058
**Document Hash:** cb925df5c530204672653a5db2955723
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001575872-25-000570.hdr.sgml**: 20250911

**ACCESSION NUMBER**: 0001575872-25-000570

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 5

**CONFORMED PERIOD OF REPORT**: 20250910

**FILED AS OF DATE**: 20250911

**DATE AS OF CHANGE**: 20250911

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** DR REDDYS LABORATORIES LTD
- **CENTRAL INDEX KEY:** 0001135951
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** K7
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-15182
- **FILM NUMBER:** 251307529

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034
- **BUSINESS PHONE:** 91 40 49002900

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 8-2-337, ROAD NO.3 BANJARA HILLS
- **CITY:** HYDERABAD
- **PROVINCE COUNTRY:** K7
- **ZIP:** 500-034

#### <br>

#### SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

Form 6-K

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16** 

#### UNDER THE SECURITIES EXCHANGE ACT OF 1934
**September, 2025**

**Commission File Number 1-15182**

**DR. REDDY'S LABORATORIES LIMITED**

(Translation of registrant's name into English)

**8-2-337, Road No. 3, Banjara Hills**

**Hyderabad, Telangana 500 034, India**

#### +91-40-49002900
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ⌧&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F ◻

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ◻ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No ⌧

If "Yes" is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.

**EXHIBITS** 

---

| | |
|:---|:---|
| **Exhibit** <br>**Number** | **Description of Exhibits** |
| [99.1](rdy0801_ex99-1.htm) | [Intimation dated September 10, 2025](rdy0801_ex99-1.htm) |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) | DR. REDDY'S LABORATORIES LIMITED<br>(Registrant) |
| Date: September 10, 2025  | By: | /s/ K Randhir Singh | /s/ K Randhir Singh |
|  |  | Name: | K Randhir Singh |
|  |  | Title: | Company Secretary |

---

## Exhibit 99.1

**Exhibit 99.1**

**Dr. Reddy's Laboratories Ltd.**<br>8-2-337, Road No. 3, Banjara Hills<br>Hyderabad – 500 034, Telangana, India <br>CIN: L85195TG1984PLC004507<br>Tel:&nbsp;&nbsp;&nbsp;&nbsp; + 91 40 4900 2900<br>Fax: + 91 40 4900 2999<br>Email: <u>mail@drreddys.com</u><br>Web: <u>www.drreddys.com</u><br>

September 10, 2025

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/ Madam,

**Ref: <u>Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")</u>**

This is to inform you that Dr. Reddy's Laboratories Limited (Dr. Reddy's) has entered into a definitive agreement with Janssen Pharmaceutica NV (JPNV) (naamloze vennootschap), an affiliate of Johnson & Johnson, to acquire the STUGERON<sup>®</sup> brand, including its leading local brands, Stugeron<sup>®</sup> FORTE and Stugeron<sup>®</sup> PLUS as well as its related assets (hereinafter referred to as 'STUGERON<sup>®</sup> portfolio') across 18 markets in the Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions, with India and Vietnam as key markets.

Further, the details as required under Regulation 30 of the SEBI Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, are as hereunder:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;1 | &nbsp;&nbsp;Name of the entity(ies) with whom agreement/ JV is signed | &nbsp;&nbsp;Janssen Pharmaceutica NV (naamloze vennootschap), an affiliate company of Johnson & Johnson  |
| &nbsp;&nbsp;2 | &nbsp;&nbsp;Area of agreement/ JV | &nbsp;&nbsp;Acquisition of the STUGERON<sup>®</sup> portfolio across 18 markets in the APAC and EMEA regions. |
| &nbsp;&nbsp;3 | &nbsp;&nbsp;Domestic/ international | &nbsp;&nbsp;Domestic and International – Dr. Reddy's has acquired the STUGERON*<sup>®</sup>* portfolio across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets. |
| &nbsp;&nbsp;4 | &nbsp;&nbsp;Share exchange ratio/ JV ratio | &nbsp;&nbsp;Not applicable |
| &nbsp;&nbsp;5 | &nbsp;&nbsp;Scope of business operation of agreement/ JV | &nbsp;&nbsp;Through this deal, Dr. Reddy's has acquired the STUGERON<sup>®</sup> portfolio from JPNV to commercialize the same across 18 markets. |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;6 | &nbsp;&nbsp;Details of consideration paid/ received in agreement/ JV | &nbsp;&nbsp;USD 50.5 million. |
| &nbsp;&nbsp;7 | &nbsp;&nbsp;Significant terms and conditions of agreement/ JV in brief | &nbsp;&nbsp;Under the terms of the agreement, Dr. Reddy's has acquired the STUGERON<sup>®</sup> portfolio in the aforesaid mentioned markets and the operations will be gradually transitioned to ensure smooth integration of the business. |
| &nbsp;&nbsp;8 | &nbsp;&nbsp;Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length | &nbsp;&nbsp;JPNV is not a related party to Dr. Reddy's or any of its promoter/promoter group/ group companies. Therefore, this acquisition deal with JPNV does not fall within related party transactions.<br>Further, promoter/promoter group/ group companies do not have any interest in JPNV.<br>|
| &nbsp;&nbsp;9 | &nbsp;&nbsp;Size of the entity(ies) | &nbsp;&nbsp;Not applicable |
| &nbsp;&nbsp;10 | &nbsp;&nbsp;Rationale and benefit expected | &nbsp;&nbsp;The acquisition strengthens Dr. Reddy's Central Nervous System (CNS) Portfolio in India and Emerging Markets through its foray into the anti-vertigo segment. |

---

A press release to be issued in relation to the above matter is enclosed for reference.

This is for your information and records.

Thanking you.

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**<br>

![](rdy0801_ex99-1img02.jpg)<br>

**K Randhir Singh**

Company Secretary, Compliance Officer & Head-CSR

Encl: As above

![](rdy0801_ex99-1img03.jpg)<br>

---

| | | |
|:---|:---|:---|
|  | **CONTACT** | **CONTACT** |
| <br>**DR. REDDY'S LABORATORIES LTD.** <br>8-2-337, Road No. 3, Banjara Hills, <br>Hyderabad - 500034. Telangana, India. | **Investor relationS** | **Media relationS** |
| <br>**DR. REDDY'S LABORATORIES LTD.** <br>8-2-337, Road No. 3, Banjara Hills, <br>Hyderabad - 500034. Telangana, India. |  |  |
| <br>**DR. REDDY'S LABORATORIES LTD.** <br>8-2-337, Road No. 3, Banjara Hills, <br>Hyderabad - 500034. Telangana, India. | Richa Periwal | PRIYA K |
| <br>**DR. REDDY'S LABORATORIES LTD.** <br>8-2-337, Road No. 3, Banjara Hills, <br>Hyderabad - 500034. Telangana, India. | <u>RICHAPERIWAL@DRREDDYS.COM</u> | <u>PRIYAK@DRREDDYS.COM</u> |

---

**Dr. Reddy's strengthens its CNS Portfolio by foraying into anti-**

**vertigo segment with acquisition of STUGERON<sup>®</sup>**

· *Dr. Reddy's enters into a definitive agreement to acquire STUGERON<sup>®</sup>portfolio* 

· *The portfolio acquired includes STUGERON<sup>®</sup> brand as well as its leading local brands Stugeron <sup>®</sup> FORTE and Stugeron <sup>®</sup> PLUS across* *18 markets in the APAC and EMEA regions, with India and Vietnam as key markets* 

**Hyderabad India; September 10, 2025** – Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as "Dr. Reddy's"), a global pharmaceutical company, today announced the completion of a definitive transaction with Johnson & Johnson\*, to acquire STUGERON<sup>®</sup> and its locally recognized brands, STUGERON<sup>®</sup> FORTE and STUGERON<sup>®</sup> PLUS, across 18 markets in the APAC and EMEA regions, with India and Vietnam as key markets.

STUGERON<sup>®</sup> contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. With STUGERON<sup>®</sup> already holding first position in the Cinnarizine represented pharmaceutical market (RPM) and ranked second in the anti-vertigo extended represented pharmaceutical market (eRPM) in India<sup>1</sup>, this acquisition presents a strategic opportunity for Dr. Reddy's to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio.

With this acquisition, Dr. Reddy's gets access to STUGERON<sup>®</sup> brand and its related portfolio in the mentioned markets and the operations will be gradually transitioned to ensure smooth integration of the business.

**M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's**, said: *"Dr. Reddy's acquisition of the STUGERON<sup>®</sup> brand reflects a steady advancement in our efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of our CNS portfolio. Backed by our strong market access, we intend to extend the reach of STUGERON<sup>®</sup> and its associated products across 18 key markets in the APAC and EMEA regions including India and Vietnam. This strategic step is in line with our broader commitment to improving patient access and advancing toward our goal of reaching over 1.5 billion patients by 2030."*

\* The agreement is between Dr. Reddy's and Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson

<sup>1</sup> IQVIA MAT July 2025

**About Dr. Reddy's**: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: <u>www.drreddys.com</u>.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. This includes but is not limited to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions (i). Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2025. The company assumes no obligation to update any information contained herein.